Home » Topics » BioWorld Science

BioWorld Science
RSS

SHR-170008 immunotherapy demonstrates antitumor efficacy in vivo

May 15, 2020

Kaleido initiates developmental program of KB-109 in mild to moderate COVID-19

May 15, 2020

Krystal Biotech announces positive interim data from phase I/II study of KB-105

May 15, 2020

FDA approves IND application for SMP-100 as treatment of IBS

May 15, 2020

Abivax receives clearance to initiate phase IIb/III study of ABX-464 COVID-19 patients

May 15, 2020

Advaxis reports positive preliminary data from ongoing phase I/II study of ADXS-503 in NSCLC

May 15, 2020

Novadip reports interim data from phase I/II bone non-union study of NVD-003

May 15, 2020

Liver-specific pre-eclampsia treatment is maternal-specific

May 15, 2020

Viela reports interim phase Ib data on VIB-7734 in cutaneous lupus erythematosus

May 14, 2020

Vyriad opens phase II trial of Voyager-V1 in combination with cemiplimab for cancer

May 14, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...